The Future of Medicine: Exploring the Pharmaceutical Drug Delivery Market's Growth by 2026

The pharmaceutical drug delivery market is on the brink of a significant transformation. According to the recent report, "Pharmaceutical Drug Delivery Market Size, Growth by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals) - Global Forecast to 2026", this market is projected to soar to an impressive USD 2,206.5 billion by 2026, growing at a CAGR of 5.9%. This growth is a testament to the continuous advancements and innovations in drug delivery technologies aimed at enhancing patient care and treatment outcomes.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

Driving Forces Behind the Growth

Innovations in Drug Delivery Technologies

Drug delivery is a critical aspect of modern medicine, encompassing methods of administering pharmaceutical compounds to achieve the desired therapeutic effect safely and effectively. Innovations in this field have led to several benefits, including increased convenience, ease of use, and improved patient compliance. Pharmaceutical and biopharmaceutical companies are heavily investing in research and development (R&D) to create new molecules for various therapeutic applications and develop advanced drug delivery platforms. This focus on innovation is crucial for delivering high-quality and groundbreaking products to the market.

Addressing Market Challenges

Despite the promising growth, the pharmaceutical drug delivery market faces certain challenges. The risk of needlestick injuries and the pressure on drug pricing are notable concerns that could potentially hinder market expansion. Companies are actively working to mitigate these issues through the development of safer delivery methods and cost-effective solutions.

Market Segmentation Insights

Route of Administration:

The market is segmented based on the route of administration into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. In 2020, the oral drug delivery segment held the largest market share. This dominance is attributed to the convenience, patient preference, cost-effectiveness, and ease of large-scale manufacturing associated with oral dosage forms.

Application Areas:

When segmented by application, the infectious diseases segment emerged as the largest market share holder. This can be linked to the rising prevalence of infectious diseases globally and the increasing number of FDA approvals for related drugs. Other significant application areas include cancer, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, and autoimmune diseases.

Facility of Use:

Hospitals accounted for the largest share of the pharmaceutical drug delivery market in 2020. The significant number of inpatient and outpatient visits, along with the growing need for large volumes of drugs and delivery devices, drives this segment. Additionally, the increasing incidence of chronic diseases, aging population, and the rising number of hospitalizations and surgical procedures contribute to this growth.

Regional Growth Prospects

The Asia Pacific region is poised to be the fastest-growing market for pharmaceutical drug delivery during the forecast period. Factors such as a rapidly aging population, rising prevalence of chronic diseases, increased healthcare expenditure, and robust R&D activities are driving this growth. Technological collaborations, favorable reimbursement policies, and rising disposable incomes in countries like China and India further bolster the market's expansion in this region.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Key Market Players:

The pharmaceutical drug delivery market is highly competitive, with several major players driving innovation and growth. Key companies include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), and many others. These companies are at the forefront of developing cutting-edge drug delivery technologies and expanding their market presence through strategic collaborations and investments.

Conclusion:

The pharmaceutical drug delivery market is set for remarkable growth, driven by technological advancements and increasing demand for effective and convenient drug delivery methods. With continuous innovations and strategic investments, the market is poised to significantly enhance patient care and treatment outcomes, making a substantial impact on global healthcare. As we look towards 2026, the future of pharmaceutical drug delivery promises to be dynamic and transformative, offering new possibilities for improved health and well-being.

Future Growth Trends in Pharmaceutical Drug Delivery

Major Growth Influencing Factors:

Increased R&D spending, the expanding biologics market, the emergence of new products, the growing prevalence of chronic illnesses, and technology breakthroughs are all major contributors to the growth of the pharmaceutical drug delivery sector. Additionally, research and development (R&D) is a priority for pharmaceutical and biopharmaceutical businesses as they create novel compounds for a range of therapeutic uses and drug delivery systems.

The companies invest heavily in R&D with the aim of delivering high-quality and innovative products to the market. R&D spending by biopharmaceutical companies has also increased over the years. On the other hand, the risk of needlestick injuries and the increased pricing pressure are expected to limit the market's growth to some extent in the coming years.

Market Size Estimation:

Following data triangulation from various methods, the pharmaceutical medication delivery market's overall size was determined, as will be discussed below. Based on the degree of assumptions made in each method, a weighted average of the techniques was determined after each one.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

Major Surge in Global Revenue:

The size of global pharmaceutical drug delivery market in terms of revenue was estimated to be worth $1,656.9 billion in 2021 and is poised to reach $2,206.5 billion by 2026, growing at a CAGR of 5.9% from 2021 to 2026.

Data Triangulation:

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Opportunity: Self-management and in-home care

Players in the pharmaceutical drug delivery market could see substantial growth prospects from self-administration and home care. The primary cause of this is the growing geriatric population, as they represent a significant market for home care medication delivery equipment. This aspect is also driving up demand for application-specific topical, injectable, inhalation, and transdermal medication treatments that meet patients' and caregivers' demands.

Challenge: Pressure on prices

Government agencies are pushing cost-cutting initiatives including lowering prescription reimbursement rates and encouraging the use of generics more frequently in both developed and developing nations. Government agencies, insurers, and patients are putting tremendous pressure on drug makers worldwide to reduce costs. Because there is a significant demand for affordable treatments in emerging countries, there is a greater adoption of pharmaceuticals as a result of this lower pricing pressure.

Still, this is hurting a number of pharmaceutical companies' bottom lines. Due to constant pressure from pharmacy benefit managers (PBMs), insurers, and public and private payers to lower pharmaceutical prices because they are worried about paying for more new medications to treat common conditions like diabetes and high cholesterol, this trend is anticipated to continue in the upcoming years.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Geographical Growth Scenario:

North America will dominate the pharmaceutical drug delivery industry from 2021–2026

Geographically, the global pharmaceutical drug delivery market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America accounted for the largest share of this market in 2020. The high share of the North American market is attributed to the rising prevalence of chronic diseases, such as cancer, respiratory allergies, and diabetes; increasing patient compliance with innovative drug delivery technologies; and the presence of a large number of prominent players in this region.

Pharmaceutical Drug Delivery: Emerging Trends to Bring Major Transformation in Near Future

Overview of This Study:

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Revenue Growth Predictions:

With a compound annual growth rate (CAGR) of 5.9%, the global pharmaceutical medication delivery industry is expected to reach $2,206.5 billion by 2026 from its anticipated $1,656.9 billion in revenue in 2021. The research report includes a price analysis, patent analysis, conference and webinar materials, important stakeholders, purchasing patterns in the market, and an analysis of industry trends.

Major Growth Driving Factors:

Growth in the pharmaceutical drug delivery industry can largely be attributed to factors such as the rising prevalence of chronic diseases, the growing biologics market, increasing R&D investments, technological advancements, and new product launches. Moreover, pharmaceutical and biopharmaceutical companies are focusing on R&D to develop new molecules for various therapeutic applications and drug delivery platforms. The companies invest heavily in R&D with the aim of delivering high-quality and innovative products to the market. R&D spending by biopharmaceutical companies has also increased over the years. On the other hand, the risk of needlestick injuries and the increased pricing pressure are expected to limit the market's growth to some extent in the coming years.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

The infectious disease segment accounted for the largest share of the pharmaceutical drug delivery industry

On the basis of application, the pharmaceutical drug delivery market is segmented into cancer, infectious diseases, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2020, the infectious diseases segment accounted for the largest share of the global market. The large share of this market segment can be attributed to the increasing prevalence of infectious diseases across the globe, increasing R&D expenditure for new drugs owing to the current COVID-19 pandemic scenario, and the rising number of FDA approvals for such drugs.

Geographical Growth Dynamics:

From 2021 to 2026, North America will lead the pharmaceutical drug delivery sector.

The pharmaceutical drug delivery market is divided geographically into the following regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2020, North America held the biggest market share in this industry. The rising incidence of chronic illnesses like diabetes, cancer, and respiratory allergies as well as patient compliance with novel drug delivery technologies and the concentration of major players in this region are all considered to be contributing factors to the market's high share in North America.

Driver: Growth in biologics market

Enterprises like Evonik (Germany) have realized the potential of biologics production and have taken significant strategic steps forward. For example, in 2021 the business acquired SurModics, a company that specializes in controlled-release parenteral applications, in order to expand its production capacity. To further strengthen its position in this industry, Evonik also purchased related technology, such as the RESOMER platform from Boehringer Ingelheim. In a similar vein, WuXi Biologics and Shanghai Hile Bio-Technology Co., Ltd. announced the establishment of WuXi Vaccines in 2019. The two businesses forged a strategic alliance whereby WuXi Vaccines will construct a special facility and provide a commercial product for the international market. A new class of medicines has emerged in the biopharmaceutical industry, demonstrating great promise for novel therapies in diabetes, cancer, and other disease areas.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Leading Companies:

Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).

Pharmaceutical Drug Delivery Market: Emerging Trends to Boost Global Growth

Global Growth Driving Factors:

Increased R&D spending, the expanding biologics market, the emergence of new products, the growing prevalence of chronic illnesses, and technology breakthroughs are all major contributors to the growth of the pharmaceutical drug delivery sector. Additionally, research and development (R&D) is a priority for pharmaceutical and biopharmaceutical companies as they create novel molecules for a range of therapeutic uses and drug delivery systems.

The companies make significant investments in R&D in order to provide the market with innovative and high-quality products. Biopharmaceutical companies have also increased their R&D spending over time. However, it is anticipated that in the upcoming years, the risk of needlestick injuries and the increased pricing pressure will somewhat restrict the market's growth.

Market Size Estimation:

Following data triangulation from various methods, the pharmaceutical drug delivery market's overall size was determined, as will be discussed below. Based on the degree of assumptions made in each approach, a weighted average of the approaches was determined after each one.

Revenue Growth Dynamics:

With a compound annual growth rate (CAGR) of 5.9%, the global pharmaceutical drug delivery market is expected to reach $2,206.5 billion by 2026 from its estimated $1,656.9 billion in revenue in 2021.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

Objectives of this Study:

# To define, describe, and forecast the pharmaceutical drug delivery market by route of administration, facility of use, application, and region.

# To provide detailed information regarding factors influencing the market growth, such as drivers, restraints, opportunities, and challenges.

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall pharmaceutical drug delivery market.

# To analyze the market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of the pharmaceutical drug delivery market in five main regions (along with their respective key countries), namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

# To profile the key players in the pharmaceutical drug delivery market and comprehensively analyze their core competencies and market shares.

# To track and analyze competitive developments, such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and product approvals of the leading players in the pharmaceutical drug delivery market.

# To benchmark players within the pharmaceutical drug delivery market using the competitive leadership mapping framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering.

Opportunity: Self-management and in-home care

Players in the pharmaceutical drug delivery market should see substantial growth prospects from self-administration and home care. The primary cause of this is the growing geriatric population, as they represent a significant market for home care medication delivery devices. This factor is also driving up demand for application-specific topical, injectable, inhalation, and transdermal drug products that meet patients' and caregivers' needs.

Challenge: Pressure on prices

Government agencies are pushing cost-cutting initiatives like lowering prescription reimbursement rates and encouraging the use of generics more frequently in both developed and developing nations. Government agencies, insurers, and patients are putting tremendous pressure on drug manufacturers worldwide to reduce costs. Because there is a high demand for affordable therapeutics in emerging markets, there is a greater uptake of drugs as a result of this downward pricing pressure. Still, this is hurting a number of pharmaceutical companies' bottom lines.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Due to constant pressure from pharmacy benefit managers (PBMs), insurers, and public and private payers to lower pharmaceutical prices because they are worried about paying for more new medications to treat common conditions like diabetes and high cholesterol, this trend is anticipated to continue in the upcoming years.

Geographical Growth Dynamics:

Among companies involved in the pharmaceutical drug delivery market, Asia Pacific is anticipated to have the highest compound annual growth rate.

Asia Pacific is anticipated to grow at the fastest rate among regional markets for pharmaceutical drug delivery during the forecast period. The APAC market is anticipated to grow during the forecast period due to a number of factors, including the rapidly aging population, the rising prevalence of chronic diseases, the rise in healthcare spending, the increased R&D activities carried out in this region, the expansion of technological collaborations for pharmaceutical drug delivery technologies, the favorable reimbursement policies, and the rise in disposable incomes in the emerging Asian economies, like China and India.

Global Leading Players:

Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), among others.

Growth Strategies Opted by Them:

These companies are primarily focused on strategies such as agreements, product launches, acquisitions, partnerships, collaborations, and expansions in order to maintain their competitiveness and increase their market share.

Read the Detailed Report, Here@
https://www.marketsandmarkets.com/Market-Reports/drug-delivery-technologies-market-1085.html

Pharmaceutical Drug Delivery: Harnessing the Benefits of Modern Drug Delivery Solutions

Reasons Behind Global Industry Growth:

The pharmaceutical drug delivery market is growing due to the increasing demand for effective and efficient drug delivery systems, the growing prevalence of chronic diseases and the elderly population, the increasing focus on drug safety and efficacy, the rising demand for personalized medicine, the growing use of nanotechnology in drug delivery, the increasing focus on self-administration, the development of smart drug delivery systems, and the increasing use of biologics and biosimilars.

Growth Driving Factors:

# Rising prevalence of chronic diseases
# Growth in the biologics market
# Technological advancements and new product launches
# Increasing investments in pharmaceutical R&D

Benefits of Advanced Pharmaceutical Drug Delivery Solutions:

Increased Drug Efficiency:

Advanced pharmaceutical drug delivery solutions help to maximize the efficiency of drugs, as they can deliver more of the active ingredient to the target area while minimizing the amount of drug that is wasted. This helps to reduce the overall cost of the treatment and can also result in improved patient outcomes.

Improved Patient Compliance:

Advanced drug delivery solutions provide an easy and convenient way for patients to take their medication, which can help to improve compliance. This can reduce the risk of drug resistance, as patients are more likely to take their medication as prescribed.

Reduced Side Effects:

Advanced drug delivery systems are designed to deliver the drug more precisely, which can reduce the risk of side effects. This can improve patient comfort and can also reduce the risk of serious adverse reactions.

Reduced Treatment Costs:

Advanced drug delivery solutions can help to reduce the overall cost of treatment, as they can help to maximize the efficiency of the drug and reduce the amount of drug that is wasted. This can help to reduce the overall cost of treatment, making it more affordable for patients.

Get the PDF Brochure to Read More Detailed Information..!

Major Stakeholders in This Industry:

# Pharmaceutical companies
# Drug delivery system manufacturers
# Regulatory authorities
# Market research and consulting firms
# Government and industry associations
# Academic institutes and universities
# Venture capitalists and investors

Global Leading Companies:

The prominent players in this market are Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), among others.

Growth Strategies Adopted by These Players:

# Product Development: Key players in the pharmaceutical drug delivery market have adopted product development as a growth strategy to develop their product portfolio and expand their customer base.

# Mergers and Acquisitions: Key players have adopted mergers and acquisitions as a growth strategy to expand their businesses, gain access to innovative technologies, and improve their competitive advantage.

# Strategic Partnerships: Key players have adopted strategic partnerships as a growth strategy to collaborate with other businesses in order to gain access to new markets, technologies, and customers.

# Expansion: Key players have adopted expansion as a growth strategy to enter new markets, expand their customer base, and increase their revenue.

# Cost Reduction: Key players have adopted cost reduction as a growth strategy to reduce their operational costs and increase their profits.

# Branding and Marketing: Key players have adopted branding and marketing as a growth strategy to increase their visibility and create customer loyalty.

You Can Also Connect With Our Experts to Get All Your Doubts Cleared..!

Pharmaceutical Drug Delivery Market - Rising Demand for Biosimilars and Biologics

 Major Growth Driving Factors:

Growth in the Pharmaceutical Drug Delivery Market can largely be attributed to factors such as the rising prevalence of chronic diseases, the growing biologics market, increasing investments in pharmaceutical R&D, and increasing technological advancements. The rising demand for biosimilars & biologics and self-administration & home care provides a wide range of growth opportunities for key players in the market.

On the other hand, the risk of needlestick injuries and the increased pricing pressure is expected to limit the market growth to some extent in the coming years. Further, the COVID-19 pandemic affected world economics, including the pharmaceutical sector. While currently there is no definitive treatment for this novel infectious disease, the pharmaceutical industry is assisting government bodies to address the COVID-19 unmet needs, from R&D actions on potential treatment and prevention strategies to balancing the medicines supply chain in the time of crisis.

Projected Revenue Surge:

The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period.

Challenge: Pricing pressure

Government bodies in both developed and developing countries are encouraging cost-saving measures, such as cutting drug reimbursement prices and promoting the greater use of generics. Drug manufacturers across the globe are facing significant cost reduction pressures from government bodies, insurers, and patients. This downward pricing pressure is resulting in the greater uptake of drugs in emerging markets where the demand for low-cost therapeutics is high.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

The infectious diseases segment is expected to account for the largest share of the pharmaceutical drug delivery market

Based on application, the pharmaceutical drug delivery market is segmented into cancer, infectious diseases, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2020, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this market segment can be attributed to the increasing prevalence of infectious diseases across the globe, increasing R&D expenditure for new drugs owing to the current COVID-19 pandemic scenario, and the rising number of FDA approvals for such drugs.

The topical drug delivery segment is expected to grow at the highest CAGR during the forecast period

Based on route of administration, the pharmaceutical drug delivery market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery segment accounted for the highest CAGR of the pharmaceutical drug delivery market. This can be attributed to convenience and the ease of use, the ease of dosage, painless and non-invasive administration, and enhanced patient compliance.

Recent Developments:

# In July 2021, Johnson & Johnson received FDA approval for DARZALEX (daratumumab), a subcutaneous formulation that reduces the treatment time for multiple myeloma indications.

# In December 2020, Pfizer, Inc. received FDA approval for BRAFTOVI (encorafenib) plus combination with cetuximab for the treatment of patients with brafv600e-mutant metastatic colorectal cancer (CRC) who have undergone prior therapy.

# In November 2020, GlaxoSmithKline plc partnered with IDEAYA to enter the field of Synthetic Lethality, an emerging field in oncology; programs MAT2A, Pol Theta, and Werner Helicase programs, which are part of it, are projected to reach clinical trials in the next three years.

Asia Pacific is expected to account for the highest CAGR for players operating in the pharmaceutical drug delivery market

During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market for pharmaceutical drug delivery. The rapid rise in the geriatric population, increased prevalence of chronic diseases, increased healthcare expenditure, increased R&D activities conducted in this region, growth in technological collaborations for pharmaceutical drug delivery technologies, favorable reimbursement policies, and growth in disposable incomes in the emerging Asian economies, such as China and India, are factors that are expected to drive the growth of the APAC market during the forecast period.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Key Market Players:

Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).

Pharmaceutical Drug Delivery Market worth $2,206.5 billion by 2026

 Overview:

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Expected Revenue Growth:

The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period. Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.

The topical drug delivery segment is expected to grow at the highest CAGR during the forecast period

Based on route of administration, the pharmaceutical drug delivery market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery segment accounted for the highest CAGR of the pharmaceutical drug delivery market. This can be attributed to convenience and the ease of use, the ease of dosage, painless and non-invasive administration, and enhanced patient compliance.

The infectious diseases segment is expected to account for the largest share of the pharmaceutical drug delivery market

Based on application, the pharmaceutical drug delivery market is segmented into cancer, infectious diseases, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2020, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this market segment can be attributed to the increasing prevalence of infectious diseases across the globe, increasing R&D expenditure for new drugs owing to the current COVID-19 pandemic scenario, and the rising number of FDA approvals for such drugs.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

Asia Pacific is expected to account for the highest CAGR for players operating in the pharmaceutical drug delivery market

During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market for pharmaceutical drug delivery. The rapid rise in the geriatric population, increased prevalence of chronic diseases, increased healthcare expenditure, increased R&D activities conducted in this region, growth in technological collaborations for pharmaceutical drug delivery technologies, favorable reimbursement policies, and growth in disposable incomes in the emerging Asian economies, such as China and India, are factors that are expected to drive the growth of the APAC market during the forecast period.

Market Size Estimation:

The total size of the pharmaceutical drug delivery market was arrived at after data triangulation from different approaches, as mentioned below. After each approach, the weighted average of the approaches was taken based on the level of assumptions used in each approach.

Data Triangulation:

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Key Players:

Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Pharmaceutical Drug Delivery Market - All You Need to Know Emerging Trends by 2026

 About the Report:

Drug delivery is the method or process of administration of a pharmaceutical drug to safely attain its desired therapeutic effect. Advancements in drug delivery technologies offer several benefits, such as ease of use, convenience, and patient compliance. Drug developers are focusing on suitable delivery and packaging options for increasing the efficiency of drugs and proposing improved patient compliance.

Pharmaceutical and biopharmaceutical companies are focusing on R&D to develop new molecules for various therapeutic applications and drug delivery platforms. The companies invest majorly in R&Ds with an aim to deliver high-quality and innovative products to the market. R&D spending by biopharmaceutical companies has also increased over the years.

Expected Revenue Growth:

The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period. 

Major Growth Boosting Factors:

Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

On the other hand, the risk of needlestick injuries and the increased pricing pressure is expected to limit the market growth to some extent in the coming years.

Driver: Growth in biologics market

Recognizing the potential for biologics manufacturing, companies, such as Evonik (Germany), have made several strategic developments. For instance, the company increased its production capacity by acquiring SurModics in 2021, which focuses on controlled-release parenteral applications. In addition, Evonik acquired complementary technologies, such as Boehringer Ingelheim’s RESOMER platform, to improve its capability in this market.

Similarly, in 2019, WuXi Biologics announced the launch of WuXi Vaccines, a joint venture with Shanghai Hile Bio-Technology Co., Ltd. The companies entered into the strategic partnership under which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market. The biopharmaceutical industry has witnessed the emergence of a new class of therapeutics, showing significant potential in new treatments in oncology, diabetes, and other disease areas.

Opportunity: Self-administration and home care

Self-administration and home care are expected to provide significant growth opportunities for players operating in the pharmaceutical drug delivery market. This is mainly due to the rising geriatric population, as elderly individuals form a large consumer base for drug delivery devices for home care. This factor is also increasing the need for application-specific injection, inhalation, topical, and transdermal drug products that are designed to cater to the needs of caregivers and patients.

Challenge : Pricing pressure

Government bodies in both developed and developing countries are encouraging cost-saving measures, such as cutting drug reimbursement prices and promoting the greater use of generics. Drug manufacturers across the globe are facing significant cost reduction pressures from government bodies, insurers, and patients. This downward pricing pressure is resulting in the greater uptake of drugs in emerging markets where the demand for low-cost therapeutics is high.

However, this is affecting the profitability of several pharmaceutical companies. This trend is expected to continue in the coming years owing to the continuous pressure for reducing pharmaceutical prices by insurers, pharmacy benefit managers (PBMs), and public and private payers due to concerns about covering more new medicines to treat prevalent conditions, such as high cholesterol and diabetes.

North America will dominate the pharmaceutical drug delivery market from 2021–2026

Geographically, the global pharmaceutical drug delivery market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the largest share of the pharmaceutical drug delivery market in 2020. The high share of the North American market is attributed to the rising prevalence of chronic diseases, such as cancer, respiratory allergies, and diabetes; increasing patient compliance to innovative drug delivery technologies; and the presence of a large number of prominent players in this region.

Recent Developments:

# In July 2021, Johnson & Johnson received FDA approval for DARZALEX (daratumumab), a subcutaneous formulation that reduces the treatment time for multiple myeloma indications.

# In December 2020, Pfizer, Inc. received FDA approval for BRAFTOVI (encorafenib) plus combination with cetuximab for the treatment of patients with brafv600e-mutant metastatic colorectal cancer (CRC) who have undergone prior therapy.

# In November 2020, GlaxoSmithKline plc partnered with IDEAYA to enter the field of Synthetic Lethality, an emerging field in oncology; programs MAT2A, Pol Theta, and Werner Helicase programs, which are part of it, are projected to reach clinical trials in the next three years.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Key Players:

Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).

Pharmaceutical Drug Delivery Market - Major Factors Boosting Global Industry Revenue

 Overview of This Study:

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Driver: Growth in biologics market

Recognizing the potential for biologics manufacturing, companies, such as Evonik (Germany), have made several strategic developments. For instance, the company increased its production capacity by acquiring SurModics in 2021, which focuses on controlled-release parenteral applications. In addition, Evonik acquired complementary technologies, such as Boehringer Ingelheim’s RESOMER platform, to improve its capability in this market. Similarly, in 2019, WuXi Biologics announced the launch of WuXi Vaccines, a joint venture with Shanghai Hile Bio-Technology Co., Ltd.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

Projected Surge in Revenue Generation:

The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period.

Opportunity: Self-administration and home care

Self-administration and home care are expected to provide significant growth opportunities for players operating in the pharmaceutical drug delivery market. This is mainly due to the rising geriatric population, as elderly individuals form a large consumer base for drug delivery devices for home care. This factor is also increasing the need for application-specific injection, inhalation, topical, and transdermal drug products that are designed to cater to the needs of caregivers and patients.

Market Size Estimation

The total size of the pharmaceutical drug delivery market was arrived at after data triangulation from different approaches, as mentioned below. After each approach, the weighted average of the approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Challenge : Pricing pressure

Government bodies in both developed and developing countries are encouraging cost-saving measures, such as cutting drug reimbursement prices and promoting the greater use of generics. Drug manufacturers across the globe are facing significant cost reduction pressures from government bodies, insurers, and patients. This downward pricing pressure is resulting in the greater uptake of drugs in emerging markets where the demand for low-cost therapeutics is high. 

However, this is affecting the profitability of several pharmaceutical companies. This trend is expected to continue in the coming years owing to the continuous pressure for reducing pharmaceutical prices by insurers, pharmacy benefit managers (PBMs), and public and private payers due to concerns about covering more new medicines to treat prevalent conditions, such as high cholesterol and diabetes.

Asia Pacific is expected to account for the highest CAGR for players operating in the pharmaceutical drug delivery market

During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market for pharmaceutical drug delivery. The rapid rise in the geriatric population, increased prevalence of chronic diseases, increased healthcare expenditure, increased R&D activities conducted in this region, growth in technological collaborations for pharmaceutical drug delivery technologies, favorable reimbursement policies, and growth in disposable incomes in the emerging Asian economies, such as China and India, are factors that are expected to drive the growth of the APAC market during the forecast period.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Global Leading Companies:

Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).